Ryu Kariyawasam-Chavez, Content Associate

Pharmacy Times interviews Kamel Lahouel, PhD, and Cristian Tomasetti, PhD, on the challenges of predicting MHC class II peptide binding and how combining structural and sequence-based models can improve accuracy while addressing key limitations.

Pharmacy Times interviews Lorin Fisher, PhD, BCACP, on her presentation, “Gabapentin for Pain Management: Well Done or Overdone?,” presented at the SPPCP conference. Fisher discusses the evolving role of gabapentin in pain care, highlighting where evidence supports its use, where it may be overprescribed, and key considerations for pharmacists in optimizing safe and appropriate therapy.

Pharmacy Times interviewed Kimlin Ashing and Narissa Nonzee about their work examining how housing status, race, and ethnicity drive cancer screening disparities.

Enrique Velazquez Villarreal, MD, PhD, used a conversational AI platform to unify microbiome, genomic, clinical, and social determinants of health data for colorectal cancer research.

Research presented at the American Association for Cancer Research Annual Meeting shows personalized mRNA vaccine immunotherapy targets pancreatic cancer tumor neoantigens, sparking durable T-cell responses and boosting survival in a phase 1 clinical trial.

Emerging data find buprenorphine in pregnancy matches methadone for autism and ADHD risk, supporting safer opioid MOUD access in pharmacy care.

Amber Clemmons PharmD, BCOP, FHOPA, highlights key changes in evidence grading, shared decision-making, and dosing strategies in neutropenia management.

Gwen Nichols shares her dream of changing the landscape of pediatric cancer research and care.

WHI data link radon exposure to higher ovarian cancer risk and deaths; learn how home testing may reduce cancer risk in high-radon areas.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highlighting novel hematology-oncology options and key pharmacist considerations.

Cristian Tomasetti, PhD, explains how obesity enlarges organs, raising cancer risk, and how GLP-1 weight loss therapy may reverse this, guiding oncology pharmacists.

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.

LTOT opioid therapy declines, but gabapentinoid coprescribing rises—impact on chronic pain management, safety, and prescriptions.

Therapy-related acute myeloid leukemia (tAML) increases as cancer therapy improves, spotlighting AML risk after chemotherapy or radiation and the need for vigilant oncology monitoring.

Phase 3 trial data show that isatuximab quadruplet improves MRD negativity in transplant-eligible patients with multiple myeloma.

Meitheal Pharmaceuticals launches propofol sedation vials for ICU and surgery, cutting waste and dosing errors with 3 single-dose sizes.